Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in BAP1 and Other DDR Pathway Deficient Neoplasms
NCT03207347Phase 2Completed
- Sponsor
- University of Florida
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in mesothelioma, Uveal melanoma (UM), renal cell carcinoma (RCC), cholangiocarcinoma (CCA), sponsored by University of Florida. Started Aug 2018; status: completed.
02
Drugs
niraparib
03
Conditions
mesotheliomaUveal melanoma (UM)renal cell carcinoma (RCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03207347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207347.